These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30950925)

  • 41. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.
    Gosmanova EO; Canada RB; Mangold TA; Rawls WN; Wall BM
    Am J Med Sci; 2008 Sep; 336(3):241-7. PubMed ID: 18794619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.
    Bowker SL; Yasui Y; Veugelers P; Johnson JA
    Diabetologia; 2010 Aug; 53(8):1631-7. PubMed ID: 20407744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients.
    Suh DC; Lee DH; McGuire M; Kim CM
    Curr Med Res Opin; 2011 Aug; 27(8):1623-33. PubMed ID: 21696266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
    Holman RR; Thorne KI; Farmer AJ; Davies MJ; Keenan JF; Paul S; Levy JC;
    N Engl J Med; 2007 Oct; 357(17):1716-30. PubMed ID: 17890232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
    Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH
    Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
    JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score-Matched Study.
    Lee YHA; Zhou J; Hui JMH; Liu X; Lee TTL; Hui K; Chan JSK; Wai AKC; Wong WT; Liu T; Ng K; Lee S; Dee EC; Zhang Q; Tse G
    J Natl Compr Canc Netw; 2022 Jun; 20(6):674-682.e15. PubMed ID: 35714677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.
    Wu Y; Liu HB; Shi XF; Song Y
    PLoS One; 2014; 9(6):e99577. PubMed ID: 24924771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
    Zhang Z; Cao Y; Tao Y; E M; Tang J; Liu Y; Li F
    Diabetes Res Clin Pract; 2020 Jan; 159():107990. PubMed ID: 31866530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations.
    Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN
    Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
    Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L
    Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.
    Campi R; Brookman-May SD; Subiela Henríquez JD; Akdoğan B; Brausi M; Klatte T; Langenhuijsen JF; Linares-Espinos E; Marszalek M; Roupret M; Stief CG; Volpe A; Minervini A; Rodriguez-Faba O
    Eur Urol Focus; 2019 Nov; 5(6):1029-1057. PubMed ID: 29661588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent metformin adherence and the risk of hypoglycaemia in the year following intensification with a sulfonylurea.
    Min JY; Griffin MR; Chipman J; Hackstadt AJ; Greevy RA; Grijalva CG; Hung AM; Roumie CL
    Diabet Med; 2019 Apr; 36(4):482-490. PubMed ID: 30378161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
    BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration.
    Dimic D; Velojic Golubovic M; Antic S; Radenkovic S
    Bratisl Lek Listy; 2009; 110(6):335-9. PubMed ID: 19634573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.